门诊静脉热消融术后血栓预防实践:瑞士全国调查
瑞士全国调查评估门诊静脉热消融术后血栓预防和随访方案,121名医生回复(回复率62.7%)。大多数医生使用药物性血栓预防,首选直接口服抗凝药,但首次给药时机和持续时间差异大,反映缺乏高质量循证指南。
要点
- 71.1%的医生总是使用药物性血栓预防,77.3%首选直接口服抗凝药。
- 血栓预防持续时间1-21天,57名医生使用7-10天。
- 99.2%常规进行消融后双功超声随访,EHIT管理因分级而异。
核心结论
- 大多数医生在静脉热消融术后使用药物性血栓预防,首选直接口服抗凝药。
- 首次给药时机和预防持续时间差异大,反映缺乏高质量循证指南。
研究设计与样本
- 全国性问卷调查,发送给瑞士所有193名静脉热消融认证医生,回复121份,回复率62.7%。
主要发现
- 71.1%的医生总是使用药物性血栓预防,6.6%几乎总是,4.1%经常,17.4%很少,0.8%从不。
- 77.3%的医生首选直接口服抗凝药作为血栓预防类型。
- 53.7%的医生在干预后立即给予首剂血栓预防。
- 血栓预防持续时间范围为1至21天,57名医生使用7至10天。
- 所有医生均使用压力治疗,单次消融后及伴随静脉切除术后的持续时间范围均为1至42天。
关键数值与推荐
- 药物性血栓预防使用频率:总是71.1%,几乎总是6.6%,经常4.1%,很少17.4%,从不0.8%。
- 直接口服抗凝药为首选类型,占77.3%。
- 消融后双功超声常规随访由99.2%的回复者进行,69.4%进行2至3次扫描。
临床怎么用
- 多数医生使用药物性血栓预防,首选直接口服抗凝药,但时机和持续时间需个体化。
- 常规进行消融后双功超声随访,EHIT管理应根据分级进行。
局限性
- 调查基于问卷回复,存在应答偏倚可能。
- 未提供高质量证据-based指南,实践差异大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The use of endovenous thermal ablation (ETA) for the treatment of truncal varicose veins has been increasing worldwide; however, uncertainty remains regarding the need for thromboprophylaxis and follow-up of patients undergoing this minimally invasive procedure. A nationwide survey of among physicians performing ETA was conducted to assess the thromboprophylaxis practice and follow-up protocols after ETA in Switzerland. METHODS: A questionnaire was sent to all ETA-certified physicians (n = 193) in Switzerland. The survey covered procedure type, thromboprophylaxis (including pharmacologic and compression therapy), duplex ultrasound follow-up examinations, and the management of endovenous heat-induced thrombosis (EHIT). RESULTS: Overall, 121 responses were received, for a response rate of 62.7%. Of the 121 respondents, 71 were vascular medicine specialists (58.7%) and 46 were general or vascular surgeons (38.0%), representing the two largest groups of specialists, followed by 2 dermatologists (1.7%) and 2 interventional radiologists (1.7%). Pharmacologic thromboprophylaxis after ETA was always used by 86 physicians (71.1%), nearly always by 8 (6.6%), frequently used by 5 (4.1%), rarely used by 21 (17.4%), and never by 1 physician (0.8%). A direct oral anticoagulant drug was the preferred type of thromboprophylaxis used by 92 physicians (77.3%). The first dose of thromboprophylaxis was mostly administered immediately after intervention by 53 physicians (53.7%). The duration of postablation thromboprophylaxis ranged from 1 to 21 days, with 7 to 10 days used by 57 physicians. Compression therapy was used by all physicians, with large variation in duration ranging from 1 to 42 days after a single ETA session and after ETA with concomitant phlebectomy. Postablation duplex ultrasonography was performed routinely by 120 respondents (99.2%), and 84 respondents (69.4%) performed two to three duplex ultrasound scans. Management of EHIT depended on the EHIT class and differed widely among the physicians. CONCLUSIONS: Our nationwide survey on thromboprophylaxis practices after ETA of truncal varicose veins in Switzerland showed that most physicians use pharmacologic thromboprophylaxis, with a direct oral anticoagulant drug the preferred agent. However, the timing of the first dose and the duration of thromboprophylaxis varied widely among the respondents, reflecting the uncertainty in this domain owing to the absence of high-quality evidence-based guidelines.
引用
- Keo HH, Knoechel J, Spinedi L, et al. Thromboprophylaxis practice after outpatient endovenous thermal ablation. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33263288. doi:10.1016/j.jvsv.2020.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。